NDRA vs. NUWE, HSDT, NBY, FNCH, SNES, INVO, PHIO, REVB, ALBT, and ARDS
Should you be buying ENDRA Life Sciences stock or one of its competitors? The main competitors of ENDRA Life Sciences include Nuwellis (NUWE), Helius Medical Technologies (HSDT), NovaBay Pharmaceuticals (NBY), Finch Therapeutics Group (FNCH), SenesTech (SNES), INVO Bioscience (INVO), Phio Pharmaceuticals (PHIO), Revelation Biosciences (REVB), Avalon GloboCare (ALBT), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "medical" sector.
Nuwellis (NASDAQ:NUWE) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
ENDRA Life Sciences has a net margin of 0.00% compared to ENDRA Life Sciences' net margin of -202.97%. Nuwellis' return on equity of -204.78% beat ENDRA Life Sciences' return on equity.
In the previous week, ENDRA Life Sciences had 5 more articles in the media than Nuwellis. MarketBeat recorded 8 mentions for ENDRA Life Sciences and 3 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.38 beat ENDRA Life Sciences' score of -0.05 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.
ENDRA Life Sciences received 216 more outperform votes than Nuwellis when rated by MarketBeat users. Likewise, 62.67% of users gave ENDRA Life Sciences an outperform vote while only 50.00% of users gave Nuwellis an outperform vote.
3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 2.6% of Nuwellis shares are owned by insiders. Comparatively, 4.8% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ENDRA Life Sciences has lower revenue, but higher earnings than Nuwellis. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Nuwellis has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Summary
ENDRA Life Sciences beats Nuwellis on 11 of the 14 factors compared between the two stocks.
Get ENDRA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ENDRA Life Sciences Competitors List
Related Companies and Tools
